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1 Introduction
Heart failure (HF) not only presents a formidable challenge 
to clinicians but also constitutes an enormous economic 
burden on society today. The current clinical treatment of 
severely decreased contractility relies either on mechanical 
support or on conventional positive inotropic agents, which 
increase contraction by increasing intracellular Ca2+. How-
ever, the prognosis of HF remains poor. Genetic manipula-
tion (i.e., gene transfer) or the use of stem cells to reverse 
HF offers an alternative possibility for a cure. So far, gene 
therapy has failed※. Cell regeneration techniques are still in 
their experimental stages and are not without risks or limi-
tations. In the meantime, new knowledge on the regulation 
of force generation by myoﬁ laments has revolutionized our 
search for new ways to boost cardiac contractility. It is clear 
that post-translational modiﬁ cations (PTMs) of myoﬁ lament 
proteins are important modulatory mechanisms of cardiac 
force development. Calcium sensitizers, a class of drugs that 
increase the effectiveness of a given amount of calcium in 
generating force, have been a recent focus of investigation [1]. 
Mechanistically, most calcium sensitizers produce PTMs by 
introducing themselves into the molecular structure of the 
regulatory proteins in order to increase the proteins’ affin-
ity to Ca2+. Somewhat disappointingly, these kinds of PTMs 
increase diastolic force, thus worsening diastolic dysfunction 
in HF or causing cardiac arrhythmias. By interacting with 
critical cysteine residues of the contractile proteins, nitroxyl 
(HNO) alters the redox states of the proteins and produces 
unique PTMs to increase cardiac contractility. The growing 
popularity of HNO as a novel inotropic agent is evidenced by 
recent studies that show that the new intravenous HNO do-
nor, CXL-1020, signiﬁ cantly improves contractile function in 
HF dogs [2, 3], and by the fact that CXL-1020 has entered into 
phase I/II clinical trial※※. 
2 What is HNO?
Nitroxyl or nitrosyl hydride (HNO) is the one-electron reduc-
tion product of nitric oxide (NO•), and has a distinctive chem-
istry from that of NO• [4]. Currently, there are no deﬁ nitive 
methods available to unequivocally detect the “footprints” 
of HNO in a biological system because of its relatively short 
half-life (i.e., < 2.7 min, based on current HNO donors in a bi-
ological buffer system). However, there is plenty of evidence 
for its generation in in vitro studies, most of which are nitric 
oxide synthase (NOS)-dependent pathways [5]. At present, 
the endogenous generation of HNO (pathways) is specula-
tive; however, some recent evidence shows that endogenous 
molecules can act as substrates for HNO formation, render-
ing its endogenous biosynthesis even more likely [5].
3 What cardiac effect does HNO exert?
The ﬁ rst report of HNO cardiovascular action was by Fukuto 
et al. [6], which showed that the HNO donated by Angeli’s 
salt (AS, Na2N2O3) could relax rabbit aortas and bovine intra-
pulmonary arteries via an sGC-dependent mechanism. We 
and our collaborators have investigated the biological effects 
of HNO during the past few years. Dr. Paolocci et al. [7] have 
shown that the administration of HNO causes an increase in 
left ventricular contractility with concomitant reduction in 
preload, in the presence of peripheral vasodilation. Impor-
tantly, the positive inotropic action of HNO can be prevented 
by thiol-donating compounds such as N-acet yl-L-cysteine 
[7], while HNO displays full cGMP- and β-receptor indepen-
dency in vivo [8].
3.1 Effect of HNO on cardiac excitation-contraction (EC) coupling in 
a normal heart
Contraction and force generation in cardiac muscle are trig-
gered by the generation of membrane action potential, which 
allows the entry of a small amount of Ca2+ into the myocyte 
via the sarcolemmal voltage-dependent Ca2+ channels (L-
type Ca2+ channels). This entry triggers the release of a bigger 
pulse of Ca2+ from the sarcoplasmic reticulum (SR) through 
specialized Ca2+-gated channels (i.e., ryanodi ne receptors 
(RyR2)). This event is known as Ca2+-induced Ca2+ release [9]. 
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The released Ca2+ binds to troponin C (TnC), one of the three 
regulatory troponins (TnC, TnI, and TnT). Ca2+ binding to 
the single site in the NH2 domain of cardiac TnC triggers a 
strong binding of this domain with the COOH terminal and 
with the central regions of TnI [10]. This binding between the 
two troponin subunits alters their molecular conformations 
[11, 12], and causes: ① release of the TnI inhibitory region 
(residues 136–147) from its interaction with F-actin-tropomy-
osin (Tm) and ② weakening of the interaction between the 
C-terminal region of TnI and Tm. As a result, Tm moves over 
the actin surface, exposing the sites on actin for the myosin 
head to bind, resulting in contraction.
Recent studies have shown that HNO enhances cardiac 
Ca2+ cycling by stimulating RyR2 to enhance SR Ca2+ frac-
tional release without recruiting extracellular Ca2+ from L-
type channel activity [13, 14]. Interestingly, the induced in-
otropy was sustained by stimulating the activity of SR Ca2+ 
ATPase (SERCA2a). This is because HNO activates SERCA2a 
in a manner that resembles the β-adrenergic/PKA-dependent 
removal of inhibition exerted by phospholamban (PLN) due 
to SERCA2a activation by the selective modification of cys-
teines in PLN [15]. We have also shown that HNO increases 
force relative to Ca2+ in cardiac muscle as a result of increased 
responsiveness of myoﬁ lament to Ca2+ [16, 17]. At ﬁ xed exter-
nal Ca2+, HNO increases more force than intracellular Ca2+ 
transients. Thus, HNO is a Ca2+ sensitizing agent. The effects 
of HNO on increasing intracellular Ca2+ transients and myo-
ﬁ lament Ca2+ responsiveness are synergistic, as we have re-
cently shown in phospholamban-deﬁ cient mice (unpublished 
results). At the molecular level, HNO induces the formation 
of a disulﬁ de bond between cysteines. 
The positive inotropic effect is also prevented and reversed 
by dithiothreitol (DTT), conﬁ rming HNO sensitivity to redox 
conditions. Thus, HNO uniquely modifies the redox state 
of the contractile proteins such that a positive inotropic ef-
fect is achieved. This effect is in contrast to the “overhaul” of 
redox state by reactive oxygen species (ROS), which results 
in signiﬁ cant depression of contractility [18–20]. Another im-
portant aspect of HNO’s action is that HNO does not deplete 
glutathione [21].
3.2 Effect of HNO on cardiac EC coupling in a failing heart
A prominent feature of failing myocardium is increased 
oxidative stress [22, 23]. Increased oxidative stress (or “redox 
imbalance”) can result in key events that determine or are as-
sociated with the onset and progression of congestive heart 
failure (CHF) disease. These events include altered EC cou-
pling, cardiomyocyte maladaptive hypertrophy, extracellular 
matrix remodeling, abnormal tissue energetics, loss of viable 
myocardium, vascular and capillary alterations, and inﬂ am-
mation. All of these events will eventually lead to signiﬁ cant 
remodeling of the heart, signified by increased chamber 
dilation and loss of contractility. There are two featured 
changes in failing myocardium worth mentioning: ① The 
β-adrenergic system (which adjusts cardiac force develop-
ment to increased work demand) is downregulated in CHF 
due to β-receptor desensitization to and uncoupling from sig-
naling molecules [24]; ② oxidation of myofilament proteins 
has been found and implicated in the depressed contractility 
in HF [20, 25–27]. These proteins include actin, Tm, and myo-
sin light chain 1 (MLC1). Oxidation of myoﬁ laments can re-
sult in the formation of carbonyl groups and protein-protein 
cross-linkages [28]. Since the decreased contractility is revers-
ible and redox-dependent, cysteine residues appear to be the 
primary targets, as supported by the formation of Tm-Tm 
and actin-actin dimers. 
As discussed above, HNO also targets cysteines with simi-
lar redox-dependency and reversibility; however, it augments 
contractility. Can HNO still increase force development in 
failing myocardium in which some cysteine residues have 
already been oxidized? The answer is yes. In a dog with 
pacing-induced HF, Paolocci et al. [8] were able to show that 
HNO improved both contractility and relaxation to a similar 
extent as in control preparations. Further, when HNO was 
administered concomitantly with β-agonist mimetics such 
as dobutamine, they were additive in supporting myocar-
dial contraction; as opposed to NO/nitrite, which blunted 
dobutamine-induced enhancement in function. The new in-
travenous HNO donor, CXL-1020, signiﬁ cantly improved con-
tractile function in both HF dogs and in patients with HF [29]. 
In isolated cardiac muscles from mice models of HF, HNO 
also increased force development directly (unpublished data). 
However, the exact mechanism by which HNO augments 
force development in failing myocardium with increased 
oxidative stress (or altered redox signaling) is still an area of 
intense investigation. 
4 Future directions in HNO research as a unique 
positive inotropic agent
Redox imbalance has been increasingly recognized as a ma-
jor mechanism of decreased contractility in HF. Oxidized 
myoﬁ lament proteins have also been found in experimental 
HF and implicated in decreases in heart function. The fact 
that HNO can still increase contraction under oxidative stress 
suggests that HNO acts in a unique way that is less affected 
by these changes. For example, it is not known whether cross-
bridge kinetics are reg ulated by redox signaling. Since HNO 
augments force development in a redox-dependent way, it 
is important to find out how HNO affects cross-bridge cy-
cling kinetics. Studies of this kind will not only uncover the 
molecular mechanism of HNO action in the heart, but also 
enrich our understanding of the PTM-induced modulation 
of the actin-activated myosin chemomechanical cycle that 
contributes to force generation, and help in the design of new 
therapies for all HF cases in which force is reduced, oxidative 
stress is increased, and other conventional inotropic agents 
may be limited in effectiveness. 
Another area of HNO research is its effect on diastolic 
function. So far, no studies have focused on this topic. How-
ever, previous studies from our laboratories have indicated 
that HNO does not alter diastolic relaxation and ATPase 
activity. Diastolic function is determined by three major 
factors: the rate of intracellular Ca2+ decline, thin-ﬁ lament 
de-activation, and the rate of cross-bridge cycling. By in-
creasing the activities of SERCA2a, HNO can promote Ca2+ 
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uptake and thus accelerate the rate of intracellular Ca2+ 
decline [13]. It remains attractive to ﬁ nd out if HNO modiﬁ es 
the cross-bridge cycling rate such that the force generated by 
a cross-bridge is higher with unchanged (or faster) detach-
ments (i.e., relaxation).
Our previous studies indirectly demonstrated that HNO 
enhancement of EC50 and Fmax d epends, at least in part, on 
its modification of some cysteine residues in myofilament 
contractile or regulatory proteins [16, 17]. However, a direct 
proof of that can be achieved only by replacing critical cys-
teine residues with alanines. Moreover, as per our previous 
studies, HNO can modify additional residues such as Cyst 
475 in MyBPC [17]. Yet whether this modiﬁ cation is incidental 
or functionally relevant is unknown. Therefore, experiments 
involving mutagenesis of the targeted cysteine residues will 
provide direct evidence for HNO’s myoﬁ lament actin at the 
molecular level.
Finally, no studies have tested yet whether endogenous 
oxidants such as H2O2, at predicted physiological levels, can 
differently affect force generation, and eventually where 
(H2O2) targets. Moreover, the effect of HNO on HF should be 
investigated in models of HF in vivo, especially where maxi-
mal Ca2+-activated force is signiﬁ cantly depressed. 
5 Concluding remarks
In treating HF, therapeutic interventions aiming at generat-
ing more force at the myoﬁ lament levels can be summarized 
by three classes of molecules: calcium sensitizers, myosin ac-
tivators, and HNO donors. The ﬁ rst class of drugs increases 
the effectiveness of a given amount of calcium in generating 
force. Most calcium sensitizers produce PTMs by introduc-
ing themselves into the molecular structure of the regulatory 
proteins in order to increase the proteins’ affinity to Ca2+. 
However, these kinds of PTMs increase diastolic force, thus 
worsening diastolic dysfunction in HF or causing cardiac 
arrhythmias. Myosin activators are recently discovered 
force-promoting molecules [30], which also increase dia-
stolic force. By interacting with critical cysteine residues of 
the contractile proteins, HNO donors represent a new and 
redox-based class of drugs that increases cardiac contractility 
independently of β-adrenergic stimulation, without altering 
diastolic tension and ATP consumption. Thus, HNO-medi-
ated PTMs hold great promise of success for the treatment 
of HF: The efficacy of HNO is expected to be sustained or 
enhanced because of the depletion of potential intracellular 
thiol buffers and because of its resistance to ROS scavenging. 
Thus, this unique, novel, redox-related regulator of cardiac 
contractility will shed light in generating new strategies to 
treat HF patients.
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